Benzinga | Jan 10, 2022 10:57AM EST

UPDATE: Longeveron Says Expects To Publish Phase 1 Trial Results For Alzheimer's Disease Trial In 2022; Expects To Rapidly Recruit, Enroll Phase 2a Trial

https://www.sec.gov/Archives/edgar/data/1721484/000121390022001252/ea153758ex99-1_longeveron.htm